Sera Prognostics, Inc. (NASDAQ:SERA) Director Sells $94,054.00 in Stock

Sera Prognostics, Inc. (NASDAQ:SERA) Director Joshua Phillips sold 12,710 shares of the business’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the completion of the sale, the director now directly owns 5 shares in the company, valued at $37. This trade represents a 99.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Joshua Phillips also recently made the following trade(s):

• On Monday, January 13th, Joshua Phillips sold 12,163 shares of Sera Prognostics stock. The shares were sold at an average price of $6.39, for a total transaction of $77,721.57.

Sera Prognostics Stock Down 2.7 %

NASDAQ:SERA opened at $6.42 on Friday. The firm has a market capitalization of $216.80 million, a PE ratio of -6.48 and a beta of 0.86. Sera Prognostics, Inc. has a 12-month low of $4.98 and a 12-month high of $12.35. The firm has a 50-day moving average price of $7.37 and a 200 day moving average price of $7.31.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same quarter in the prior year, the company posted ($0.23) EPS. On average, research analysts expect that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Barclays PLC grew its holdings in shares of Sera Prognostics by 321.6% in the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after purchasing an additional 30,093 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Sera Prognostics by 100.2% in the second quarter. Bank of New York Mellon Corp now owns 150,708 shares of the company’s stock valued at $892,000 after buying an additional 75,441 shares in the last quarter. Geode Capital Management LLC grew its stake in Sera Prognostics by 8.9% during the third quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after buying an additional 47,969 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after buying an additional 5,415 shares in the last quarter. Finally, State Street Corp raised its stake in shares of Sera Prognostics by 8.8% in the third quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after acquiring an additional 34,479 shares during the last quarter. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.